📰 4 sources covering this story

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine - WSJ

First covered 9 hrs ago · latest take 2 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine - WSJ
Moderna Shares More Than Double on Success of mRNA Cancer Vaccine - WSJ
Moderna Shares More Than Double on Success of mRNA Cancer Vaccine  WSJ
Reuters
Reuters5 hrs ago
Moderna shares double as cancer vaccine data rekindles investor hopes
Moderna shares double as cancer vaccine data rekindles investor hopes  Reuters
Fast Company
Fast Company7 hrs ago
Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening
Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.  The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results
MarketWatch
MarketWatch🏁 first to report9 hrs ago
Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →